Business
Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs.
About this update from Arno Therapeutics Inc
[{"type":"text","content":"\nFLEMINGTON, N.J., Sept. 19, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced promising data demonstrating novel activity of AR-12 as a broad-spectrum, anti-microbial drug. Results were presented over the weekend in a podium presentation and in posters at ICAAC/ICC 2015 (Interscience Conference of Antimicrobial Agents and Chemotherapy / International Congress of Chemotherapy and Infection), which is jointly hosted by the American Society for Microbiology (ASM) and International Society of Chemotherapy (ISC) and took place September 17-21 in San Diego, CA.\n\n\tStefan Proniuk, PhD, Chief Development Officer of Arno Therapeutics, who presented an in vitro inhibition of chikungunya virus replication by AR-12 in a podium presentation on Saturday, September 19, commented, \"Prior AR-12 antiviral investigations demonstrate potent activity across a wide range of distinct pathogenic viruses such as Influenza A, Epstein Barr virus, and hemorrhagic fever viruses including Ebola, Marburg, Nipah, Lasa, Junin, and Yellow fever. In the two studies we presented at ICAAC/ICC, we now show that AR-12 has a first-in-class, novel mechanism of action that enables its potential for broad-spectrum antimicrobial activity, providing additional rationale for the continued development of the compound against a number of infectious disease targets.\"\n\n\tConclusions from the two Arno presentations on AR-12 are as follows:\n\n\tPodium Presentation: The Host Cell Targeting Molecule AR-12 Inhibits Chikungunya Virus Replication In Vitro\n\n\t\n\t\tPresenting Author: Stefan Proniuk, PhD\n\t\n\t\tPoster Session: Current Research on Respiratory and Other Viruses\n\t\n\t\tDate, Time: Saturday, September 19; 10:30 AM – 10:45 AM PT\n\t\n\t\tResults from a preclinical study assessing broad-spectrum antiviral activity of AR-12 demonstrate that the drug's first-in-class, novel mechanism of action has the potential for a broad-spectrum antiviral activity including the Chikungunya virus and has the potential to be used in combination with existing antiviral agents which may reduce the emergence of treatment resistant viral pathogens. \n\t\n\t\tActivity of AR-12 was evaluated ag...